Grants and Contributions:
Title:
Biomarker Validation of ClarityDX, a Blood Test to Predict Aggressive Prostate Cancer
Agreement Number:
903707
Agreement Value:
$413,000.00
Agreement Date:
Apr 1, 2018 - Mar 31, 2020
Description:
The Nanostics-IRAP project involves refinement and validation of the ClarityDx biomarker panel. ClarityDx is a novel liquid biopsy test that accurately predicts prostate cancer from just a few drops of blood.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Edmonton, Alberta, CA T6H 3E2
Reference Number:
172-2018-2019-Q3-903707
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
707942124
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The total amended value is 44,000 dollars.
Amendment Date
Feb 25, 2020
Recipient's Legal Name:
Nanostics Inc.
Federal Riding Name:
Edmonton Strathcona
Federal Riding Number:
48019
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: